R&D	Innovative R&D Home Multiple Sclerosis Franchise Other Neurological/Neurodegenerative Diseases Auto-Immune/Inflammatory Diseases Oncology

Innovative Research & Development

Teva has been engaged in innovative research and development for over two decades now. During this period, it has made significant progress, mainly in two therapeutic fields: central nervous system (CNS ) and autoimmune (AI) diseases. Oncology is recently emerging as a potential new area (see Table). These efforts culminated in 2 innovative products introduction into global markets : Copaxone® ( glatiramer acetate) for MS and Azilect® for Parkinson's disease (PD).

Most of the current pipe-line projects are based on research performed in the leading research institutes and start-up companies in Israel. With the acquisition of Ivax at the beginning of 2006, Teva's Innovative pipe-line has been enriched with several new molecules in clinical and pre-clinical stages of development. Attempts have been recently initiated towards licensing-in of promising products from additional non-Israeli sources.

Multiple Sclerosis Franchise

Product	Indication	Status
Copaxone® (glatiramer acetate for Injection)	Relapsing-Remitting MS (R-R MS)	Approved world-wide. Phase IIIb/IV studies on-going, including a study in CIS patients , a study with a daily 40mg dose and various combination/induction protocols
Laquinimod	Relapsing MS	Phase III
Various other programs		Research

Other Neurological/Neurodegenerative Diseases

Product	Indication	Status
Azilect® (rasagiline mesylate)	Parkinson's disease	Approved world-wide as a symptomatic treatment for both early patients, as monotherapy, and advanced patients, as adjuncive treatment to levodopa. A Phase IIIb to show effect on disease progression is on-going
Glatiramer acetate	ALS	Phase II
Rasagiline mesylate	Alzheimer's disease	Phase II
Talampanel	ALS	Phase II
Various other programs		Research

Auto-Immune/Inflammatory Diseases

Product	Indication	Status
Edratide	Lupus	Phase II in SLE
TV-3813	Psoriasis	Pre-clinical
Various other programs		Research

Oncology

Product	Indication	Status
Stem Ex® (with Gamida-Cell)	Hemato-oncological indications	Phase III
Talampanel	Glioma	Phase II
Various other programs		Research